AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16172147
Drug: Two etonogestrel
RxNorm normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two etonogestrel rods (204 mg etonogestrel) and 400 mg testosterone decanoate every 6 weeks (group II, n = 51)
Trial: 16172147
Drug: Two etonogestrel
RxNorm normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two etonogestrel rods (204 mg etonogestrel) and 600 mg testosterone decanoate every 6 weeks (group III, n = 37)
Trial: 14669843
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol valerate (E2V) + 3 mg dienogest (DNG)
Trial: 11079281
Drug: 20 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 minutes of education on the use of a metered-dose inhaler (MDI)-spacer device
Trial: 8646142
Drug: Pituitary suppression
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pituitary suppression with a luteinising hormone releasing hormone analogue followed by low dose ovulation induction and luteal phase progesterone
Trial: 24754328
Drug: Oral prenatal
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prenatal probiotic (Florajen3) taken once daily
Trial: 9862412
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration 5 min prior to word presentation
Trial: 9862412
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration immediately before word presentation
Trial: 9862412
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration immediately following word presentation
Trial: 9862412
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration 10 min prior to word presentation
Trial: 9862412
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration 5 min following word presentation
Trial: 9862412
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration 10 min following word presentation
Trial: 9862412
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration for 2 min during the experiment
Trial: 7638804
Drug: Nebulised morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised morphine (10 mg)
Trial: 7638804
Drug: Nebulised morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised morphine (25 mg)
Trial: 7638804
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (1 mg)
Trial: 7638804
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (2.5 mg)
Trial: 2692816
Drug: Theophylline (5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (5.5 mg of the ethylendiamine salt.kg‐1 intravenously)
Trial: 31508863
Drug: Tramadol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (1 mg/kg) with paracetamol (1 g)
Trial: 25209313
Drug: Patient self-testing
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient self-testing (PST) weekly
Trial: 25209313
Drug: Patient self-testing
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient self-testing (PST) twice weekly
Trial: 23638622
Drug: Raloxifene hydrochloride
RxNorm normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride (60 mg/day) for 12 weeks
Trial: 21205325
Drug: Polypill (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill (75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril, 12.5 mg hydrochlorothiazide)
Trial: 21205325
Drug: Standard Practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Practice (individual drugs)
Trial: 19419544
Drug: Traditional antiepileptic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional antiepileptic drugs
Trial: 16968583
Drug: Fixed-combination of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-combination of dorzolamide/timolol (DTFC; dorzolamide 2.0%/timolol maleate 0.5%)
Trial: 15367414
Drug: Myocet (M;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myocet (M; 75 mg/m(2)) + cyclophosphamide (C; 600 mg/m(2))
Trial: 15367414
Drug: Epirubicin (E;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (E; 75 mg/m(2)) + cyclophosphamide (C; 600 mg/m(2))
Trial: 11967795
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (2-32 mg) over a median period of 84 days (range: 1-418 days)
Trial: 9174296
Drug: alfentanil 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 40 microg/kg followed by propofol 2 mg/kg
Trial: 9174296
Drug: alfentanil 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 40 microg/kg followed by etomidate 0.3 mg/kg
Trial: 9174296
Drug: alfentanil 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 40 microg/kg followed by thiopental 4 mg/kg
Trial: 9174296
Drug: d-tubocurarine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-tubocurarine 3 mg followed by thiopental 4 mg/kg and succinylcholine 1 mg/kg
Trial: 8465885
Drug: Buspirone added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone added to fluvoxamine therapy
Trial: 3763655
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg penbutolol and 3 mg piretanide
Trial: 29780062
Drug: Chlorella (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorella (6 g/day)
Trial: 29780062
Drug: Placebo (7.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (7.2 g/day lactose)
Trial: 26807672
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg intravenously over 40 min)
Trial: 25264974
Drug: WEBCARE (12-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WEBCARE (12-week fixed, six-lesson behavioral treatment based on cognitive behavioral therapy)
Trial: 19898831
Drug: Exenatide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (5 microg subcutaneous)
Trial: 12425803
Drug: Pantoprazole triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole triple regimen (pantoprazole 40 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 1-week)
Trial: 12425803
Drug: Omeprazole triple
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 1-week)
Trial: 12425803
Drug: Pantoprazole triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole triple regimen (pantoprazole 40 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 2-weeks)
Trial: 12425803
Drug: Omeprazole triple
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 2-weeks)
Trial: 7047341
Drug: Oxmetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxmetidine (400 mg b.i.d.)
Trial: 23361158
Drug: Cholecalciferol (50,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (50,000 IU weekly for 12 weeks followed by 50,000 IU every other week for 40 weeks)
Trial: 17047649
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin (30 mg/m²), epirubicin (50 mg/m²), and paclitaxel (120 mg/m²) with granulocyte-colony stimulating factor support (PET)
Trial: 17047649
Drug: Tri-weekly epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-weekly epirubicin (90 mg/m²) and paclitaxel (175 mg/m²) (ET)
Trial: 17047649
Drug: Weekly cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin, epirubicin, and paclitaxel (PET)
Trial: 17047649
Drug: Tri-weekly epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-weekly epirubicin and paclitaxel (ET)
Trial: 11760527
Drug: Injection speed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection speed of 10 s/cc
Trial: 11760527
Drug: Injection speed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection speed of 30 s/cc
Trial: 8161675
Drug: Single-dose sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose sodium phosphate solution regimen (Fleet Phospho-Soda)
Trial: 3745848
Drug: Regular coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular coffee (100 ml)
Trial: 3745848
Drug: Decaffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated coffee (100 ml)
Trial: 3745848
Drug: Sugared water
RxNorm normalized name: SUGAR/WATER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugared water (100 ml)
Trial: 3745848
Drug: Regular coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular coffee (50 ml)
Trial: 20609130
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BoNT‐A) administered intradermally and subcutaneously, 5 units/site, total dose 40-200 units.
Trial: 15855884
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy (estrogen and gestagen)
Trial: 10806378
Drug: Fluoroquinolone antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroquinolone antibiotics (FQ)
Trial: 8638526
Drug: Nitrates alone
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrates alone or in combination with hydralazine
Trial: 8638526
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing of nitrates
Trial: 8638526
Drug: Escalating dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating dose regimen of nitrates with hydralazine
Trial: 1503483
Drug: Modified FAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FAM (5-FU + ADR + MMC) therapy
Trial: 1503483
Drug: 5-FU mono-therapy
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU mono-therapy
Trial: 6476623
Drug: Intermittent rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent rectal diazepam (0.5 mg/kg every 8 hours during fever)
Trial: 6476623
Drug: Oral phenobarbital
RxNorm normalized name: phenobarbital Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral phenobarbital (BID)
Trial: 29533112
Drug: Focused ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused ultrasound treatment
Trial: 26854906
Drug: MVA85A-IMX313 (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA85A-IMX313 (low dose)
Trial: 26854906
Drug: MVA85A-IMX313 (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA85A-IMX313 (standard dose)
Trial: 17177960
Drug: Nicotine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (7 mg transcutaneous patch)
Trial: 16000961
Drug: Low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-2 (3 x 10(6) IU/m2/d) administered subcutaneously for 42 days
Trial: 12387527
Drug: N 25
RxNorm normalized name: oxygen 25 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N 25 mg
Trial: 12387527
Drug: N 50
RxNorm normalized name: Ovcon 50
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: N 50 mg
Trial: 8137624
Drug: GES/EE (gestodene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GES/EE (gestodene 75 mcg/ethinyl oestradiol 30 mcg)
Trial: 8137624
Drug: DES/EE (desogestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DES/EE (desogestrel 150 mcg/ethinyl oestradiol 20 mcg)
Trial: 2536537
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of calcitriol
Trial: 2536537
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of active forms of vitamin D3
Trial: 22995539
Drug: E(2)V/DNG oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E(2)V/DNG oral contraceptive
Trial: 21774987
Drug: 12-month socioculturally
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month socioculturally adapted collaborative care (psychotherapy and/or antidepressants, telephone symptom monitoring/relapse prevention)
Trial: 19631861
Drug: PTFE ACUSEAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTFE ACUSEAL patch
Trial: 19631861
Drug: Hemashield Finesse
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hemashield Finesse patch
Trial: 19631861
Drug: PTFE ACUSEAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTFE ACUSEAL patch and Hemashield Finesse patch
Trial: 15213476
Drug: Structured nursing
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured nursing intervention (12 consecutive weekly meetings)
Trial: 9641732
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily growth hormone injection (group A)
Trial: 9641732
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily growth hormone injections (group B)
Trial: 7853436
Drug: Mebendazole treatment
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole treatment in Group A
Trial: 7853436
Drug: Mebendazole treatment
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole treatment in Group B
Trial: 7853436
Drug: Mebendazole treatment
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole treatment in Group C
Trial: 2910422
Drug: Infusor (Baxter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusor (Baxter Healthcare Corporation) for outpatient CVI chemotherapy
Trial: 2910422
Drug: Standard inpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard inpatient CVI chemotherapy delivery device (standard pump)
Trial: 2910422
Drug: Infusor (Baxter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusor (Baxter Healthcare Corporation) for inpatient CVI chemotherapy
Trial: 2910422
Drug: Outpatient CVI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient CVI chemotherapy
Trial: 2910422
Drug: CVI chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVI chemotherapy (both methods)
Trial: 1130305
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (small daily dose)
Trial: 22959620
Drug: Synbiotic (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic (6 g, two daily doses)
Trial: 21292332
Drug: Steroid antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid antibiotic pack (Betnovate-N: betnovate sodium phosphate 0.1% and neomycin sulphate 0.5%)
Trial: 19479252
Drug: GIPET-enhanced oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIPET-enhanced oral acyline 10 mg
Trial: 19479252
Drug: GIPET-enhanced oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIPET-enhanced oral acyline 20 mg
Trial: 19479252
Drug: GIPET-enhanced oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIPET-enhanced oral acyline 40 mg
Trial: 26356398
Drug: Baclofen (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (50 mg/day) for 3 months
Trial: 21547598
Drug: BMMC +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMMC + CRTinact (BMMC therapy only)
Trial: 21547598
Drug: BMMC +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMMC + CRTact (BMMC therapy + CRT)
Trial: 16161123
Drug: Lyophilized bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized bone chips supplemented with platelet gel (PG)
Trial: 16161123
Drug: Lyophilized bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized bone chips without gel
Trial: 11100985
Drug: intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intra-arterial chemotherapy
Trial: 11100985
Drug: systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: systemic chemotherapy
Trial: 11100985
Drug: multimodality combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multimodality combination and sequential treatment
Trial: 8960716
Drug: Physostigmine (18,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (18, 24, or 30 mg daily)
Trial: 19959493
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH; 5000 IU twice daily)
Trial: 19959493
Drug: Treatment modalities
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment modalities (both enoxaparin and UFH)
Trial: 17669110
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg once daily (ALL-500 group)
Trial: 17669110
Drug: Levofloxacin 1000
RxNorm normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 1000 mg twice daily (ALL-1000 group)
Trial: 17669110
Drug: Post-treatment value
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment value of (13)C-urea breath test <= 15 in ALL-500 group
Trial: 17669110
Drug: Post-treatment value
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment value of (13)C-urea breath test > 15 in ALL-500 group
Trial: 17669110
Drug: Post-treatment value
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment value of (13)C-urea breath test <= 15 in ALL-1000 group
Trial: 17669110
Drug: Post-treatment value
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment value of (13)C-urea breath test > 15 in ALL-1000 group
Trial: 16478369
Drug: Concurrent feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent feedback group (real-time EMG waveform displays)
Trial: 7534450
Drug: Hebrew version
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hebrew version of the MAP administered to Israeli children
Trial: 20727
Drug: Diazepam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.2 to 0.6 mg/kg)
Trial: 20727
Drug: Flunitrazepam (equipotent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (equipotent doses)
Trial: 21297074
Drug: Tifacogin 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tifacogin 0.025 mg/kg/h
Trial: 10769331
Drug: Bran treatment
RxNorm normalized name: bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bran treatment (gradually increasing daily doses of a bran mixture)
Trial: 9152656
Drug: Frusemide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 40 mg o.d.
Trial: 9152656
Drug: Ibopamine 100
RxNorm normalized name: ibopamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine 100 mg t.d.s.
Trial: 3739583
Drug: Intravenous methohexitone
RxNorm normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methohexitone
Trial: 30802723
Drug: Fuji apple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuji apple intake (2 apples, 360 g per day for 1 week)
Trial: 17227902
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m2 every 28 days
Trial: 27798749
Drug: Capecitabine 1250
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1250 mg/m2 twice daily for 14 days every 21 days
Trial: 25138661
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g dose of the whole-grain fibre composite ingredient
Trial: 25138661
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g dose of the whole-grain fibre composite ingredient
Trial: 25138661
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of the whole-grain fibre composite ingredient